NeuroSense Therapeutics Ltd.
NRSN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001875091
No open-market purchases or sales by NeuroSense Therapeutics Ltd. insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $285.7K in total; no superinvestor holds it.
Other share classesNRSNW
Q4 2021 vs. Q3 2021
How the institutions holding NeuroSense Therapeutics Ltd. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 0 | 5 | +5 |
| Shares | 0 | 155.0K | +155.0K |
| Value | $0 | $380.0K | +$380.0K |
New holders (5)
Institutions that held NeuroSense Therapeutics Ltd. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Hudson Bay Capital Management LP | 75,000 | $184.0K | 0.00% |
| Citadel Advisors LLC | 55,119 | $135.0K | 0.00% |
| Warberg Asset Management LLC | 15,501 | $38.0K | 0.01% |
| UBS Group AG | 8,018 | $20.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 1,323 | $3.00K | 0.00% |
Sold out (0)
Institutions that held NeuroSense Therapeutics Ltd. at the end of Q3 2021 and filed for Q4 2021 without it.
None.